Catalyst Pharmaceutical Partners (CPRX)

[homdance]

My favorite part is:

Raghuram Selvaraju, Aegis Capital Corp. (1/8/14) "In the past week, Catalyst Pharmaceutical Partners Inc. has reported that it successfully completed a Type B meeting with the U.S. Food and Drug Administration on its lead drug candidate, Firdapse, and also released positive human safety data demonstrating that the cardiac side effect profile of Firdapse is clean. . .in the wake of the positive Type B meeting and clean safety data, we maintain our Buy rating and 12-month price target of $6/share."